Please assess the completion status of the following clinical trial:

Trial Title: To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of low tumour burden, CD20+ follicular lymphoma~* Ann Arbor Stage II, III or IV~Exclusion Criteria:~* Has receive rituximab~* Allergies or hypersensitivity to murine, chimeric, human or humanised proteins~* Previous treatment for NHL~* Any malignancy~* Current or recent treatment with any other investigational medicinal product or device~* pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P10 (Type: EXPERIMENTAL): CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
- Rituxan (Type: ACTIVE_COMPARATOR): Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.

Based on this trial design, predict the completion outcome and termination type (if applicable).